Prognostic value of BRAF mutations in localized cutaneous melanoma

Background: BRAF mutations are frequent in melanoma but their prognostic significance remains unclear. Objective: We sought to further evaluate the prognostic value of BRAF mutations in localized cutaneous melanoma. Methods: We undertook an observational retrospective study of 147 patients with localized invasive (stages I and II) cutaneous melanomas to determine the prognostic value of BRAF mutation status. Results: After a median follow-up of 48 months, patients with localized melanomas with BRAF-mutant melanomas exhibited poorer disease-free survival than those with BRAF-wt genotype (hazard ratio 2.2, 95% confidence interval 1.1-4.3) even after adjustment for Breslow thickness, tumor ulceration, location, age, sex, and tumor mitotic rate. Limitations: The retrospective design and the small number of events are limitations. Conclusions: Our findings suggest that reappraisal of clinical treatment approaches for patients with localized melanoma harboring tumors with BRAF mutation might be warranted.